Objective: To quantify the progression of Parkinson disease (PD) in patients receiving inactive control treatments in three Parkinson’s disease clinical trials. Methods: Data from 1027 patients receiving pharmacologically inactive control treatments were obtained from 3 clinical trials (DATATOP, ELLDOPA,TEMPO (1-3)) and merged using SAS (9.1). Progression was modeled using a combination of a linear function […]